NeXT

StepStone Group Publishes 2023 Responsible Investment Report

Retrieved on: 
Thursday, April 25, 2024
DEI, Climate change, Principle, Social, Equity, Investment, ILPA, GP, EDCI, NeXT, ICI, Carbon, Attention, Human Capital, ESG, LP record, Socially responsible investing, PRI, Growth, Institutional Limited Partners Association, Cryptocurrency

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, has released its 2023 Responsible Investment Report , which presents an analysis of StepStone’s Environmental, Social and Governance (ESG) integration and stewardship activities, as well as an overview of the firm’s Diversity, Equity & Inclusion (DEI) performance and climate-related activities within its investments and operations.

Key Points: 
  • NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, has released its 2023 Responsible Investment Report , which presents an analysis of StepStone’s Environmental, Social and Governance (ESG) integration and stewardship activities, as well as an overview of the firm’s Diversity, Equity & Inclusion (DEI) performance and climate-related activities within its investments and operations.
  • “As the responsible investment landscape grows more complex – stemming from the inherent intricacies of many ESG considerations, such as responsible supply chains, climate change, and nature – both GPs and LPs are paying more attention,” said Suzanne Tavill, Partner and Global Head of Responsible Investment at StepStone.
  • “We appreciate the constructive support across the private markets investment community as we find solutions, clarify best practices, and seek efficiencies.”
    Highlights of the report include:
    The Responsible Investment Process: StepStone has designed a five-stage process that applies across asset classes.
  • “StepStone’s responsible investment program underpins our ability to deliver tailored investment solutions, advisory services and data-driven insights to our clients,” said Scott Hart, Partner and CEO at StepStone.

ThreatLocker® Raises $115M Series D to Continue Delivering Zero Trust Endpoint Security to More Organizations

Retrieved on: 
Wednesday, April 24, 2024
Identity, Fear, JetBlue, Partnership, NeXT, Library, Growth, Zero trust security model, General Atlantic, Enterprise, Workforce, EDR, MDR, Network Access Control, StepStone Group, Organization, Risk management

With the new investment, ThreatLocker® will continue to focus on driving product innovation to bring the power of Zero Trust security to more organizations and accelerating the company’s global expansion.

Key Points: 
  • With the new investment, ThreatLocker® will continue to focus on driving product innovation to bring the power of Zero Trust security to more organizations and accelerating the company’s global expansion.
  • ThreatLocker® provides organizations with the ability to protect their IT operations with an effective Zero Trust approach to cybersecurity.
  • We believe this new injection of capital will enable us to continue to develop Zero Trust products and grow ThreatLocker's market presence.
  • We are thrilled to further our partnership with the team to accelerate ThreatLocker’s growth as an endpoint security disruptor.”

EQS-News: Volume Production Begins for Mynaric’s Flagship Space Laser Terminal – CONDOR Mk3

Retrieved on: 
Wednesday, April 10, 2024
European Space Agency, Communication, ESA, Northrop Grumman, SDA, NeXT, FRA, Australian Space Agency, Grumman, Loft, Government

MUNICH, April 3, 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced a milestone in the product maturity of the company’s flagship free space optical communications terminal for space-to-space and space-to-ground applications - the CONDOR Mk3.

Key Points: 
  • MUNICH, April 3, 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced a milestone in the product maturity of the company’s flagship free space optical communications terminal for space-to-space and space-to-ground applications - the CONDOR Mk3.
  • Volume production for the optical communications terminal began early in the first quarter of 2024 with an initial shipment made last week following customer approval.
  • Mynaric was also selected by Loft Federal to supply the CONDOR Mk3 terminals to NExT – the SDA’s Experimental Testbed.
  • This is just the beginning of reaching our full production capacity for the CONDOR Mk3 and future products.”
    In addition to volume production of the CONDOR Mk3 optical communications system, Mynaric continues to pursue opportunities that explore the use of free space optical communications for additional space programs.

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

Retrieved on: 
Monday, April 8, 2024
NCI, Acute lymphoblastic leukemia, CLL, Immunotherapy, AML, TTC, Lung, Patient, ALL, NeXT, National Cancer Institute, Breast, Cancer, Pediatrics, Doctor of Philosophy, IND, GMP, Clinical trial, Investigational New Drug, Therapy, Immune system, Prognosis, Research institute, Cancer prevention, FDA, Lymphoma, CD127, Pharmaceutical industry

HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127. CD127 is a receptor that is expressed in major subsets of multiple cancers including hematological cancers (ALL, AML, CLL, and lymphoma) and solid tumors (lung, breast, colorectal, H&N, esophageal cancers).

Key Points: 
  • Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • HOUSTON, April 8, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT), which will support the clinical evaluation of Allterum's lead candidate, 4A10, a monoclonal antibody targeting CD127.
  • An addition to the $12M Product Development Award, Allterum received a $2.9M CPRIT seed award in 2020, which supported early-stage development work for the 4A10 antibody and laid the foundation for the current grant.
  • "We are pleased to provide Allterum with this TTC product development award to advance their promising anti-cancer drug into clinic," said Dr. Kenneth Smith, CPRIT's Chief Product Development Officer.

Freestar Supercharges Tech Agenda With Appointment of Chief Technology Officer and Additional Strategic Senior Hires

Retrieved on: 
Tuesday, March 19, 2024
NeXT, Automation, Digital marketing, Data science, Digital, SVP, Adweek, Acquisition, AI, Marketing, Burns, Machine learning, Privacy, Artificial intelligence, Advertising, Penske Media Corporation, MIQ, Video game

PHOENIX, March 19, 2024 (GLOBE NEWSWIRE) -- Freestar , the leading monetization partner for content publishers and e-commerce sites, today announced that Oliver Burns has been appointed Chief Technology Officer.

Key Points: 
  • PHOENIX, March 19, 2024 (GLOBE NEWSWIRE) -- Freestar , the leading monetization partner for content publishers and e-commerce sites, today announced that Oliver Burns has been appointed Chief Technology Officer.
  • Burns’ promotion to the role underscores Freestar’s commitment to product innovation and building the next generation of advertising technology leveraging machine learning and Artificial Intelligence in new ways.
  • Reporting to Chief Executive Officer, Kurt Donnell, Burns will oversee Freestar’s extensive ad product portfolio, maintain excellence in engineering and drive the data science and AI agenda.
  • This tripartite role provides a platform for Burns to build more award-winning solutions for Freestar’s premium publishers.

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genomics, PSNL, Immunotherapy, Patient, NeXT, Abstract, AACR, MRD, Melanoma, Neoplasm, Medical imaging

“Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal.
  • Changes in ctDNA levels detected with NeXT Personal predicted therapy response and overall survival in late-stage hepatocellular carcinoma patients treated with a personalized cancer vaccine.
  • Analytical validation of NeXT Personal demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high specificity, reinforcing the potential to detect recurrent cancer earlier.

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Genetics, Health, Oncology, WGS, Genomics, Plasma, Congress, PPM, PSNL, NSCLC, Adenocarcinoma, Patient, Publishing, DNA, Cancer, LUAD, Lung cancer, NeXT, Neoplasm, ESMO, MRD, Medicare, Recurrence, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.
  • “The robust validation results in this publication provide a foundational building block towards achieving Medicare coverage for NeXT Personal,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis.
  • “Taken together, the results show NeXT Personal’s capability for ultra-sensitive detection of ctDNA in patient plasma samples and the test’s potential to reliably inform clinicians and patients on residual cancer, cancer treatment response, and cancer recurrence through ctDNA detection, earlier than conventional detection approaches,” Chen noted.
  • This data from the TRACERx Study demonstrated the assay was able to find cancer nearly a year ahead of imaging and was predictive of clinical outcomes in early-stage lung cancer patients.

Volume Production Begins for Mynaric's Flagship Space Laser Terminal - CONDOR Mk3

Retrieved on: 
Wednesday, April 3, 2024
European Space Agency, Communication, ESA, Northrop Grumman, SDA, NeXT, FRA, Australian Space Agency, Grumman, Loft, DARPA, Government

MUNICH, April 3, 2024 /PRNewswire/ -- Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced a milestone in the product maturity of the company's flagship free space optical communications terminal for space-to-space and space-to-ground applications - the CONDOR Mk3. Volume production for the optical communications terminal began early in the first quarter of 2024 with an initial shipment made last week following customer approval.

Key Points: 
  • Volume production for the optical communications terminal began early in the first quarter of 2024 with an initial shipment made last week following customer approval.
  • Initial shipments of the CONDOR Mk3 free space optical communications system will be part of the United States Space Development Agency (SDA) Tranche 1 Transport and Tracking Layer programs, among others.
  • This is just the beginning of reaching our full production capacity for the CONDOR Mk3 and future products."
  • In addition to volume production of the CONDOR Mk3 optical communications system, Mynaric continues to pursue opportunities that explore the use of free space optical communications for additional space programs.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, PSNL, Neoplasm, Immunotherapy, Investment, DX, Lung, LDT, NeXT, Medicare, Tempus, MRD, Genomics, Partnership, Video game

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

StepStone Group Reports Third Quarter Fiscal Year 2024 Results

Retrieved on: 
Thursday, February 8, 2024
Webcast, Shareholder, PIN, NeXT

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, today reported results for the quarter ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm focused on providing customized investment solutions and advisory and data services, today reported results for the quarter ended December 31, 2023.
  • This represents results for the third quarter of the fiscal year ending March 31, 2024.
  • StepStone issued a full detailed presentation of its third quarter fiscal 2024 results, which can be accessed by visiting the Company’s website at https://shareholders.stepstonegroup.com .
  • Management will host a webcast and conference call on Thursday, February 8, 2024, at 5:00 pm ET to discuss the Company’s results for the third quarter of the fiscal year ending March 31, 2024.